Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01449422
Other study ID # FI-11-02-310 3082
Secondary ID
Status Completed
Phase Phase 4
First received October 3, 2011
Last updated March 28, 2013
Start date May 2011

Study information

Verified date March 2013
Source Laboratoires URGO
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)France: Committee for the Protection of PersonnesFrance: Conseil National de l'Ordre des MédecinsGermany: Ethics Commission
Study type Interventional

Clinical Trial Summary

The main objective of this trial is to demonstrate that a local care strategy using URGO 310 3082 dressing is not inferior to a reference therapeutic strategy using a hydrofibre dressing in the management of venous ulcers. This non-inferiority hypothesis will be judged on the planimetric relative regression of the wound surface area after six weeks of treatment.


Recruitment information / eligibility

Status Completed
Enrollment 159
Est. completion date
Est. primary completion date January 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient over 18 years old who has provided his/her written informed consent

- Patient who can be monitored by the same investigation team throughout the duration of the study

- Patient who agrees to wear effective venous compression every day, associated with the trial dressing

- Leg ulcer with a distal Ankle Brachial Pressure Index (ABPI) not less than 0.7 and not more than 1.3

- Ulcer with a minimum area of 3 cm2 and a maximum area of 30 cm2

- Ulcer duration between 3 and 36 months

- Ulcer where the surface area is 70% or more covered by fibrinous tissue

- Ulcer at least 3 cm away from any other lesion

- Ulcer moderately or strongly exudative justifying the use of an absorbent dressing

Exclusion Criteria:

- Female patient of child-bearing potential who has no effective means of contraception

- Patient who is pregnant or breastfeeding

- Patient taking part in another therapeutic trial

- Patient with hypersensitivity to one of the components of the trial dressing or a known allergy to carboxymethylcellulose (hydrocolloid)

- Patient with a serious general pathological condition who, it may be feared, might discontinue participation in the trial before the six weeks of treatment

- Patient with an evolving neoplastic condition, treated by radiotherapy, chemotherapy or hormone therapy

- Patient with a systemic infection not controlled by suitable antibiotic treatment

- Patient who, during the 3 months before inclusion, presented a deep vein thrombosis

- Ulcer where its surface is totally or partially covered by black necrotic plaque

- Ulcer which is clinically infected

- Ulcer requiring surgical treatment or for which surgery is programmed during the six weeks following inclusion

- Malignant ulcer

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Dressing
the dressing should be changed on average every 1 to 2 days, then as often as required (up to 7 days) depending on the exudate volume and the clinical condition of the wound (evaluated by the investigating doctor).
Dressing
the hydrofibre dressing should be changed when it is saturated, or depending on the clinical appreciation of the situation. The dressing can remain in place for up to 7 days.

Locations

Country Name City State
France Hopital Rothschild Paris

Sponsors (1)

Lead Sponsor Collaborator
Laboratoires URGO

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The efficacy of dressings under trial will be judged on the evolution of wound surface area after six weeks of treatment. The main evaluation criterion is the relative planimetric regression of the wound surface area, calculated according to the following formula, from centralised planimetric measurements:
Regression of the area (%) = [(ST0-STlast)/ST0] x 100 ST0: Surface area of the lesion measured on the day of inclusion STlast: Surface area of the lesion at the last planimetric evaluation available
Week 1, 2, 4 and 6 No
Secondary Comparison between the two devices of percentage of lesions in which the evolution is positive (defined by a relative regression at least 40% of wound surface) after monitoring for 6 weeks. Week 1, 2, 4 and 6 No
Secondary Comparison between the two groups of percentage of debrided lesions (defined by a lesion with more than 70% of its surface covered by granulation tissue of a "red colour" on the colorimetric scale), at the last available evaluation Week 1, 2, 4 and 6 No
Secondary Comparison between the two strategies of percentage of patients in whom at least one problem of pain was detected during care (VAS score at the end of care > 30 mm) Week 1, 2, 4 and 6 No
Secondary Comparison between the 2 groups of the percentage of wound care associated with manual debridement Week 1, 2, 4 and 6 No
Secondary Comparison between the two groups of the evolution of the patients' quality of life between inclusion and the last available visit. This quality of life will be assessed using the EuroQol-5Dâ„¢ questionnaire Week 1, 2, 4 and 6 No
Secondary Comparison between the 2 groups of the percentage of the participants number with Adverse Events Week 1, 2, 4 and 6 Yes
Secondary Comparison between the 2 groups of the mean number of dressing changes per week. Week 1, 2, 4 and 6 No
Secondary Comparison between the 2 groups of the easiness application and removal Week 1, 2, 4 and 6 No
Secondary Comparison between the 2 groups of the percentage of good or very good conformability Week 1, 2, 4 and 6 No
Secondary Comparison between the 2 groups of the mean value for overall performance score This score will be between 0 and 36 Week 1, 2, 4 and 6 No
See also
  Status Clinical Trial Phase
Withdrawn NCT02561013 - A Clinical Study to Assess a Compression Device in Patients With Venous Leg Ulcers N/A
Recruiting NCT05364112 - Utilization of Compreflex Wraps in Patients With Chronic Venous Insuffciency N/A
Completed NCT00656383 - Effectiveness and Efficiency of Two Models of Delivering Care to a Chronic Wound Population N/A
Active, not recruiting NCT02973893 - Study of VF001-DP in Patients With Chronic Venous Leg Ulcers Phase 2
Not yet recruiting NCT02873728 - Remote Ischemic Conditioning for Treatment of Chronic Wounds N/A
Completed NCT01998932 - Predictive of Biomarkers of Healing in Chronic Venous Ulceration of the Lower Limb N/A
Recruiting NCT06135246 - Laser Therapy for Venous Leg Ulcers N/A
Active, not recruiting NCT03744858 - The Role of Pyroptosis in Chronic Venous Disease
Completed NCT00838500 - THERMES ET VEINES: Spa for Prevention of Leg Ulcers Phase 3
Completed NCT04039789 - Impact of Physical Activity as a Coadjuvant Treatment in the Healing of Venous Ulcers in Primary Health Care. N/A
Completed NCT04280679 - Treatment of Insufficient Superficial and Perforatring Veins of the Lower Limb Using HIFU N/A
Completed NCT02512159 - Skin Ulcers Treatment With an Handicraft Topical Device Phase 4
Completed NCT02896725 - Wool-derived Keratin Dressings for Venous Leg Ulcers N/A
Completed NCT04310280 - Effects of Local Insulin on Varicose Ulcers for Wound Healing Phase 3
Completed NCT02626156 - Cooling Leg and Foot Ulcer Skin Post Healing to Prevent Ulcer Recurrence Phase 2
Recruiting NCT03127904 - Vein Fitness System vs Compressive Therapy for Venous Ulcers: a Bayesian Adaptive Trial N/A
Terminated NCT00727701 - Study of Individualized Wound Prevention Instruction to Prevent Venous Ulcer Development Phase 1
Withdrawn NCT00648674 - A Post-Marketing Clinical Study of Apligraf for Venous Leg Ulcers Phase 4
Completed NCT00399308 - Evaluation of Safety and Activity of Celaderm in Healing Venous Leg Ulcers Phase 1/Phase 2
Completed NCT00426972 - Trial of Zesteem (Estradiol) in Healing of Split Thickness Skin Graft Donor Sites Phase 3